TY - JOUR
T1 - Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model
AU - Wang, Z.
AU - Xu, D.
AU - Ding, Hanfei
AU - Kim, Jaejik
AU - Zhang, J.
AU - Hai, T.
AU - Yan, Chunhong
N1 - Funding Information:
This work was supported by NIH grants R01CA139107, R01CA164006 and a Department of Defense award W81XWH-07-1-0095 to CY. We thank Dr George Church for providing sgRNA targeting reagents and Dr Honglin Li for providing NF-κB reagents.
Publisher Copyright:
© 2015 Macmillan Publishers Limited All rights reserved.
PY - 2015/9/17
Y1 - 2015/9/17
N2 - Activating transcription factor 3 (ATF3) responds to diverse cellular stresses, and regulates oncogenic activities (for example, proliferation, survival and migration) through direct transcriptional regulation or protein-protein interactions. Although aberrant ATF3 expression is frequently found in human cancers, the role of ATF3 in tumorigenesis is poorly understood. Here, we demonstrate that ATF3 suppresses the development of prostate cancer induced by knockout of the tumor suppressor Pten in mouse prostates. Whereas the oncogenic stress elicited by Pten loss induced ATF3 expression in prostate epithelium, we found that ATF3 deficiency increased cell proliferation and promoted cell survival, leading to early onset of mouse prostatic intraepithelial neoplasia and the progression of prostate lesions to invasive adenocarcinoma. Importantly, the loss of ATF3 promoted activation of the oncogenic AKT signaling evidenced by high levels of phosphorylated AKT and S6 proteins in ATF3-null prostate lesions. In line with these in vivo results, knockdown of ATF3 expression in human prostate cancer cells by single guided RNA-mediated targeting activated AKT and increased matrix metalloproteinase-9 expression. Our results thus link ATF3 to the AKT signaling, and suggest that ATF3 is a tumor suppressor for the major subset of prostate cancers harboring dysfunctional Pten.
AB - Activating transcription factor 3 (ATF3) responds to diverse cellular stresses, and regulates oncogenic activities (for example, proliferation, survival and migration) through direct transcriptional regulation or protein-protein interactions. Although aberrant ATF3 expression is frequently found in human cancers, the role of ATF3 in tumorigenesis is poorly understood. Here, we demonstrate that ATF3 suppresses the development of prostate cancer induced by knockout of the tumor suppressor Pten in mouse prostates. Whereas the oncogenic stress elicited by Pten loss induced ATF3 expression in prostate epithelium, we found that ATF3 deficiency increased cell proliferation and promoted cell survival, leading to early onset of mouse prostatic intraepithelial neoplasia and the progression of prostate lesions to invasive adenocarcinoma. Importantly, the loss of ATF3 promoted activation of the oncogenic AKT signaling evidenced by high levels of phosphorylated AKT and S6 proteins in ATF3-null prostate lesions. In line with these in vivo results, knockdown of ATF3 expression in human prostate cancer cells by single guided RNA-mediated targeting activated AKT and increased matrix metalloproteinase-9 expression. Our results thus link ATF3 to the AKT signaling, and suggest that ATF3 is a tumor suppressor for the major subset of prostate cancers harboring dysfunctional Pten.
UR - http://www.scopus.com/inward/record.url?scp=84941880176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941880176&partnerID=8YFLogxK
U2 - 10.1038/onc.2014.426
DO - 10.1038/onc.2014.426
M3 - Article
C2 - 25531328
AN - SCOPUS:84941880176
SN - 0950-9232
VL - 34
SP - 4975
EP - 4984
JO - Oncogene
JF - Oncogene
IS - 38
ER -